文献速递头颈与中枢神经肿瘤

质子泵抑制剂和抗生素对纳武利尤单抗治疗复发或转移性头颈部鳞状细胞癌疗效的不利影响

Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
PubMed 文献 · Eur J Cancer · 2023-02-15

该回顾性研究纳入2017年5月至2020年3月在本院接受纳武利尤单抗治疗的铂类难治性复发或转移性头颈部鳞状细胞癌患者110例,其中56例使用质子泵抑制剂(PPI)、24例使用抗生素(Abx)。中位随访17.2个月,单变量分析显示PPI和Abx使用与所有预后参数(PFS、PFS2、PFS3、OS)的不良预后显著相关,多变量分析显示两者为相互独立的不良因素。结论认为PPI和Abx使用减弱了纳武利尤单抗的疗效,需进一步前瞻性评估。

要点

  • 复发或转移性头颈部鳞状细胞癌患者中,PPI使用与更差的总生存相关(中位OS 13.6 vs 23.8个月,HR 1.70)。
  • 抗生素使用同样与更差的总生存相关(中位OS 10.0 vs 20.1个月,HR 1.85)。
  • PPI和抗生素的不良关联在多变量分析中相互独立,但需进一步前瞻性评估。

核心结论

  • PPI和Abx的使用减弱了纳武利尤单抗在复发或转移性头颈部鳞状细胞癌中的疗效,需进一步前瞻性评估。

研究设计与样本

  • 回顾性研究,纳入2017年5月至2020年3月在本院接受纳武利尤单抗治疗的铂类难治性复发或转移性头颈部鳞状细胞癌患者110例,原发部位包括口腔、口咽、下咽和喉。

主要发现

  • 110例患者中,56例在纳武利尤单抗开始前或后30天内使用PPI,24例使用Abx。
  • 中位随访17.2个月(范围13.8-25.0),中位PFS、PFS2、PFS3和OS分别为3.2、8.1、14.0和17.2个月。
  • 单变量分析中,PPI和Abx使用与所有预后参数(PFS、PFS2、PFS3和OS)的不良预后显著相关。
  • PPI组中位OS为13.6个月 vs 非PPI组23.8个月(HR 1.70;95%CI 1.01-2.87,p=0.046)。
  • Abx组中位OS为10.0个月 vs 非Abx组20.1个月(HR 1.85;95%CI 1.00-3.41,p=0.048)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several reports have shown that the use of proton pump inhibitors (PPIs) and antibiotics (Abx) can reduce the efficacy of immune checkpoint inhibitors in various cancers. To date, however, the association of immune checkpoint inhibitors with PPI and/or Abx in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN) has not been reported. METHODS: We retrospectively reviewed patients with platinum-refractory R/M SCCHN treated with nivolumab from May 2017 and March 2020 in our institute. Primary sites included the oral cavity, oropharynx, hypopharynx and larynx. The relationship between prognostic parameters, such as overall survival (OS), progression-free survival (PFS), PFS2 and PFS3, and clinical factors, including PPI or Abx use, was examined, and the creation of prognostic classification was also attempted. RESULTS: Of 110 patients identified, 56 patients received PPI and 24 patients received Abx within 30 days before or after the initiation of nivolumab. With a median follow-up of 17.2 months (range: 13.8-25.0), median PFS, PFS2, PFS3 and OS were 3.2, 8.1, 14.0 and 17.2 months, respectively. In univariate analysis, the use of PPI and of Abx was significantly associated with poor prognosis in all parameters (PFS, PFS2, PFS3 and OS). Median OS (hazard ratio; 95%confidence interval, p-value) by these covariates were 13.6 versus 23.8 months (1.70; 1.01-2.87, p = 0.046) for PPI and 10.0 versus 20.1 months (1.85; 1.00-3.41, p = 0.048) for Abx, respectively. Furthermore, these factors showed mutually independent adverse associations on multivariate analysis. CONCLUSION: The use of PPI and Abx attenuated the efficacy of nivolumab in R/M SCCHN. Further prospective evaluation is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Wada A, Enokida T, Okano S, et al. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2023. PMID: 36898232. doi:10.1016/j.ejca.2023.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。